⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28269230 | 1.00 | — | — | |
| SCHEMBL18646649 | 1.00 | — | — | |
| SCHEMBL14950814 | 0.82 | — | — | |
| SCHEMBL25657467 | 0.82 | — | — | |
| SCHEMBL13866721 | 0.80 | — | — | |
| SCHEMBL13445989 | 0.80 | MMP2 (0.31) | — | |
| SCHEMBL24520334 | 0.78 | — | — | |
| SCHEMBL13881436 | 0.78 | MAPT (0.33) | — | |
| SCHEMBL19487337 | 0.78 | — | — | |
| SCHEMBL8300014 | 0.78 | MAPT (0.55) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720087-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | Zealand Pharma A/S (DK) | 2026-04-08 | — | — | EP | claimed |
| WO-2024246269-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | ZEALAND PHARMA A/S (DK) | 2024-12-05 | — | — | WO | claimed |
| EP-4720087-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | Zealand Pharma A/S (DK) | 2026-04-08 | — | — | EP | disclosed |
| WO-2024246269-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | ZEALAND PHARMA A/S (DK) | 2024-12-05 | — | — | WO | disclosed |
| US-20230026641-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND COMPRISING HIGHLY STERICALLY HINDERED AMINO ACID | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-01-26 | — | — | US | disclosed |
| WO-2017044633-A1 | PEPTIDOMIMETIC MACROCYCLES AS MODULATORS OF MCL-1 | AILERON THERAPEUTICS, INC. (US) | 2017-03-16 | — | — | WO | disclosed |
| US-8921319-B2 | Serine protease inhibitors | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2014-12-30 | — | — | US | disclosed |
| US-20130267467-A1 | SERINE PROTEASE INHIBITORS | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2013-10-10 | — | — | US | disclosed |
| US-8293206-B2 | Achievement of a high therapeutic index through molecular imaging guided targeted drug treatment | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2012-10-23 | — | — | US | disclosed |
| US-20100074910-A1 | Achievement of a high therapeutic index through molecular imaging guided targeted drug treatment | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20090110662-A1 | MODIFICATION OF BIOLOGICAL TARGETING GROUPS FOR THE TREATMENT OF CANCER | INTEZYNE TECHNOLOGIES, INC. (US) | 2009-04-30 | — | — | US | disclosed |